| ID  | Biomarker name | Biomarker Type | Panel or Area of Interest? | chrom | start pos  | end pos    | length | strand | Scoring Type | Result Options | Result | Is variant in coding region? | SNP ID    | Is this record the whole gene? | Illumina EPIC ID | DNA methylation region | Expression Ratio Components | Notes                                                                                                                           | References                                                                                           |
|-----|-----------------|------------------|------------------------------|-------|------------|------------|--------|--------|--------------|----------------|--------|-------------------------------|-----------|-------------------------------|---------------------|--------------------------|-------------------------------|---------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| 001 | ATG2B           | snv              | Panel                        | chr14 | 96,311,131 | 96,311,131 | 1      | -      | genotypic   | G\|G/G\|C/C\|C |        | Yes                           | rs3759601 | No                            |                     |                          |                               | Allele not associated with cancer recurrence in an Asian population but the population did not have any CC genotype              |                                                                                                      |
| 002 | NOS2            | microsatellite| AOI                         | chr17 | 27,803,068 | 27,803,263 | 196    | -      |              | (CCTTT)n       |        | No                            |           | No                            |                     |                          |                               | NOS2-promoter microsatellite (CCTTT)n, if <13 repeats, patient likely to benefit from treatment. |
| 004 | NOS3            | snv              | Panel                        | chr7  | 150,999,023| 150,999,023| 1      | +      | genotypic   | T\|T/T\|A/T\|G/A\|A/A\|G/G\|G |        | Yes                           | rs1799983 | No                            |                     |                          |                               | Homozygous GG had decreased risk - note that GT/TT patients were grouped together                                                |                                                                                                      |
| 005 | NOS3            | snv              | Panel                        | chr7  | 150,992,991| 150,992,991| 1      | +      | genotypic   | C\|C/C\|T/T\|T |        | No                            | rs2070744 | No                            |                     |                          |                               | Note that CT/CC patients were grouped together. SNP in promoter region                                                         |                                                                                                      |
| 007 | FLT1            | mod             | Panel                        | chr13 | 28,896,826 | 28,896,827 | 2      | -      | continuous   | 0.0-1.0        |        | No                            |           | No                            | cg26544530          | position                |                               |                                                                                                                                 |                                                                                                      |
| 008 | ARID1A         | area_mutations| AOI                         | chr1  | 26,728,912 | 26,780,756 | 51,845 | +      | continuous   |                | N/A    | Yes                           |           |                              |                               | Any/all mutations associated with BCG non-response                                                                               |                                                                                                      |


| ID | Biomarker name | Biomarker Type | Panel or Area of Interest? | chrom | start pos | end pos | length | strand | Scoring Type | Result Options | Result | Is variant in coding region? | SNP ID | Is this record the whole gene? | Illumina EPIC ID | DNA methylation region | Expression Ratio Components | Notes | References |  
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |   
| 004 | NOS3 | snv | Panel | chr7 | 150,999,023 | 150,999,023 | 1 | + | genotypic | T\|T/T\|A/T\|G/A\|A/A\|G/G\|G |  | Yes | rs1799983 | No |  |  |  | Homozygous GG had decreased risk - note that GT/TT patients were grouped together |   |
| 014 | FLT1 | mod | Panel | chr13 | 28,300,346 | 28,495,128 | 194,783 | - | continuous | 0.0-1.0 |  | N/A |  | Yes |  | promoter |  | has 28 CpG sites: Validated as predictive biomarker in study |   |
| 017 | IL6 | exp_ratio | Panel | chr7 | 22,725,884 | 22,732,002 | 6,119 | + | continuous | 0.0-10.0 |  | N/A |  | Yes |  |  | IL6/IL10 | IL6/IL10 ratio >0.10 associated with lower recurrence rate after BCG treatment |   |
| 018 | IL10 | exp_ratio | Panel | chr1 | 206,768,110 | 206,774,541 | 6,432 | - | continuous | 0.0-10.0 |  | N/A |  | Yes |  |  | IL6/IL10 | IL6/IL10 ratio >0.10 associated with lower recurrence rate after BCG treatment |   |
| 021 | MMP10 | expression | Panel | chr11 | 102,770,502 | 102,780,628 | 10,127 | - | continuous | 0.0-1.0 |  | N/A |  | Yes |  |  |  | Oncouria panel - Higher levels of CA9, ANG, and MMP10 prior to BCG associated with greater risk of recurrence |   |
| 024 | NOD2 | area_mutations | AOI | chr16 | 50,693,606 | 50,733,075 | 39,470 | + | continuous |  |  | N/A |  | Yes |  |  |  | Monocytes with mutations in NOD2 cannot be trained in vitro |   |
| 034 | IL18R1 | microsatellite | AOI | chr2 | 101,612,009 | 101,612,009 | 1 | + |  | GGGTGA |  | No | rs111894836 | No |  |  |  | Unclear response characteristics and relationship to gene mentioned |   |
| 401 | LMR | immune_ratio | Panel |  |  |  |  |  | continuous | 0.0-10.0 |  |  |  |  |  |  |  |  |   |
| 402 | NLR | immune_ratio | Panel |  |  |  |  |  | continuous | 0.0-10.0 |  |  |  |  |  |  |  |  |   |
| 403 | monocyte_inf | immune_inf | Panel |  |  |  |  |  | continuous | 0.0-1.0 |  |  |  |  |  |  |  |  |   |
| 405 | Bcell_inf | immune_inf | Panel |  |  |  |  |  | continuous | 0.0-1.0 |  |  |  |  |  |  |  |  |   |
| 406 | CD4_inf | immune_inf | Panel |  |  |  |  |  | continuous | 0.0-1.0 |  |  |  |  |  |  |  |  |   |
| 407 | NK_inf | immune_inf | Panel |  |  |  |  |  | continuous | 0.0-1.0 |  |  |  |  |  |  |  |  |   |
| 408 | CD8_inf | immune_inf | Panel |  |  |  |  |  | continuous | 0.0-1.0 |  |  |  |  |  |  |  |  |   |
| 409 | Treg_inf | immune_inf | Panel |  |  |  |  |  | continuous | 0.0-1.0 |  |  |  |  |  |  |  |  |   |
| 410 | Neutrophil_inf | immune_inf | Panel |  |  |  |  |  | continuous | 0.0-1.0 |  |  |  |  |  |  |  |  |   |
| 411 | Endothelial_inf | immune_inf | Panel |  |  |  |  |  | continuous | 0.0-1.0 |  |  |  |  |  |  |  |  |   |
| 412 | Eosinophil_inf | immune_inf | Panel |  |  |  |  |  | continuous | 0.0-1.0 |  |  |  |  |  |  |  |  |   |
| 413 | Fibroblast_inf | immune_inf | Panel |  |  |  |  |  | continuous | 0.0-1.0 |  |  |  |  |  |  |  |  |   |
| 414 | Cancer_inf | immune_inf | Panel |  |  |  |  |  | continuous | 0.0-1.0 |  |  |  |  |  |  |  |  |   |  


ID | Biomarker name | Scoring Type | Biomarker Type | Result Options | Result | Score |
| --- | --- | --- | --- | --- | --- | --- |    
004 | NOS3 | genotypic | snv | T\|T/T\|A/T\|G/A\|A/A\|G/G\|G | G\|G | 0.16 |
014 | FLT1 | continuous | mod - promoter region | 0.0-1.0 | 0.08 | 1.55 |
401 | LMR | continuous | immune_ratio | 0.0-10.0 | NA | NA |
402 | NLR | continuous | immune_ratio | 0.0-10.0 | 0.02 | 1.66 |
403 | Monocyte_inf | continuous | immune_inf | 0.0-1.0 | 0.00 | NA |
405 | Bcell_inf | continuous | immune_inf | 0.0-1.0 | 0.02 | 1.72 |
406 | CD4_inf | continuous | immune_inf | 0.0-1.0 | 0.00 | 
407 | NK_inf | continuous | immune_inf | 0.0-1.0 | 0.02 | 
408 | CD8_inf | continuous | immune_inf | 0.0-1.0 | 0.01 |
409 | Treg_inf | continuous | immune_inf | 0.0-1.0 | 0.14 |
410 | Neutrophil_inf | continuous | immune_inf | 0.0-1.0 | 0.00 |
411 | Endothelial_inf | continuous | immune_inf | 0.0-1.0 | 0.03 |
412 | Eosinophil_inf | continuous | immune_inf | 0.0-1.0 | 0.03 |
413 | Fibroblast_inf | continuous | immune_inf | 0.0-1.0 | 0.02 |
414 | Cancer_inf | continuous | immune_inf | 0.0-1.0 | 0.71 |
